Huynh, Hung <br/><br/>
Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.  [electronic resource] 

 -  Angiogenesis  Mar 2012 
 - 59-70 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7209 
<br/><br/><label>Standard No.: </label>10.1007/s10456-011-9243-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anilides--pharmacology<br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Apoptosis--drug effects<br/>Carcinoma, Hepatocellular--blood supply<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Liver Neoplasms--blood supply<br/>Male<br/>Mice<br/>Mice, SCID<br/>Neovascularization, Pathologic--drug therapy<br/>Quinolines--pharmacology<br/>Survival Analysis<br/>Time Factors<br/>Xenograft Model Antitumor Assays